Squarepoint
HRTX icon

Squarepoint’s Heron Therapeutics HRTX Stock Holding History

Squarepoint’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$688K Buy
859,958
+182,011
+27% +$211K ﹤0.01% 3083
2025
Q4 		$881K Buy
677,947
+462,840
+215% +$571K ﹤0.01% 2728
2025
Q3 		$271K Buy
215,107
+155,116
+259% +$246K ﹤0.01% 3751
2025
Q2 		$124K Buy
+59,991
New +$123K ﹤0.01% 4111
2024
Q4 		– Sell
-612,897
Closed -$1.22M – 5222
2024
Q3 		$1.22M Buy
612,897
+249,197
+69% +$595K ﹤0.01% 2447
2024
Q2 		$1.27M Buy
363,700
+286,160
+369% +$879K ﹤0.01% 2388
2024
Q1 		$215K Buy
+77,540
New +$195K ﹤0.01% 3575
2023
Q3 		– Sell
-160,138
Closed -$186K – 3988
2023
Q2 		$186K Buy
160,138
+134,820
+533% +$240K ﹤0.01% 3247
2023
Q1 		$38.2K Sell
25,318
-105,065
-81% -$263K ﹤0.01% 3078
2022
Q4 		$326K Sell
130,383
-77,322
-37% -$249K ﹤0.01% 2526
2022
Q3 		$877K Buy
+207,705
New +$813K ﹤0.01% 1852
2022
Q1 		– Sell
-73,893
Closed -$675K – 3140
2021
Q4 		$675K Sell
73,893
-177,108
-71% -$1.81M ﹤0.01% 1948
2021
Q3 		$2.68M Buy
251,001
+39,142
+18% +$477K 0.01% 1061
2021
Q2 		$3.29M Buy
211,859
+61,114
+41% +$972K 0.01% 925
2021
Q1 		$2.44M Buy
+150,745
New +$2.69M 0.01% 957
2020
Q4 		– Sell
-21,846
Closed -$324K – 3059
2020
Q3 		$324K Buy
+21,846
New +$341K ﹤0.01% 1738
2020
Q2 		– Sell
-211,531
Closed -$2.48M – 2349
2020
Q1 		$2.48M Buy
211,531
+131,851
+165% +$2.48M 0.06% 388
2019
Q4 		$1.87M Buy
+79,680
New +$1.76M 0.01% 943
2019
Q3 		– Sell
-70,381
Closed -$1.31M – 2481
2019
Q2 		$1.31M Sell
70,381
-7,024
-9% -$140K 0.01% 1102
2019
Q1 		$1.89M Sell
77,405
-28,179
-27% -$738K 0.02% 792
2018
Q4 		$2.74M Buy
105,584
+27,323
+35% +$751K 0.03% 580
2018
Q3 		$2.48M Buy
78,261
+29,461
+60% +$1.1M 0.03% 635
2018
Q2 		$1.9M Buy
48,800
+25,000
+105% +$796K 0.03% 650
2018
Q1 		$657K Sell
23,800
-87,784
-79% -$1.99M 0.01% 982
2017
Q4 		$2.02M Buy
111,584
+76,974
+222% +$1.26M 0.04% 559
2017
Q3 		$559K Sell
34,610
-1,303
-4% -$20.4K 0.01% 938
2017
Q2 		$497K Buy
+35,913
New +$520K 0.01% 949
2017
Q1 		– Sell
-36,467
Closed -$478K – 1689
2016
Q4 		$478K Buy
36,467
+22,367
+159% +$351K 0.02% 856
2016
Q3 		$243K Buy
14,100
+2,600
+23% +$48.2K 0.02% 821
2016
Q2 		$208K Sell
11,500
-6,300
-35% -$123K 0.01% 882
2016
Q1 		$338K Sell
17,800
-2,100
-11% -$41.4K 0.03% 781
2015
Q4 		$531K Buy
+19,900
New +$532K 0.06% 509

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Squarepoint's HRTX Position: Q1 2026 in Review

Squarepoint increased its Heron Therapeutics (HRTX) stake by 27% in Q1 2026, buying an estimated $211K and bringing the position to 859,958 shares worth $688K. The position accounts for ﹤0.01% of the portfolio, ranked #3083.

Squarepoint first reported a position in HRTX in Q4 2015 and has held it in 32 quarters since. The position peaked at $3.29M in Q2 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Squarepoint held 859,958 shares of Heron Therapeutics worth $688K as of Q1 2026.
  • Squarepoint bought 182,011 Heron Therapeutics shares in Q1 2026, an estimated $211K.
  • Heron Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3083 holding.
  • Squarepoint first reported a position in Heron Therapeutics in Q4 2015 and has held it in 32 quarters since.
  • Squarepoint's Heron Therapeutics position peaked at $3.29M in Q2 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.